Tenax Therapeutics, Inc. SEC filings TENX
Tenax Therapeutics, Inc. has 995 filings in SEC EDGAR's recent list, going back to Aug 2, 1996. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 22, 2026 | — |
| DEF 14A | Proxy statement | Apr 22, 2026 | Apr 17, 2026 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Apr 24, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 9, 2025 | Apr 9, 2025 |
| DEF 14A | Proxy statement | Sep 27, 2024 | Oct 25, 2024 |
| DEFA14A | Additional proxy material | May 24, 2024 | — |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 7, 2024 |
| DEFA14A | Additional proxy material | Oct 27, 2023 | — |
| DEF 14A | Proxy statement | Oct 27, 2023 | Oct 12, 2023 |
| PRE 14A | Preliminary proxy statement | Oct 16, 2023 | Oct 12, 2023 |
| DEFA14A | Additional proxy material | Jun 1, 2023 | — |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 9, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 14, 2023 | Apr 11, 2023 |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 9, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 13, 2022 | Jun 9, 2022 |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 10, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2021 | Jun 10, 2021 |
| DEF 14A | Proxy statement | Apr 29, 2020 | Jun 18, 2020 |
| DEF 14A | Proxy statement | Apr 19, 2019 | Jun 13, 2019 |
| DEF 14A | Proxy statement | Apr 20, 2018 | Jun 13, 2018 |
| DEF 14A | Proxy statement | Jan 16, 2018 | Feb 15, 2018 |
| PRE 14A | Preliminary proxy statement | Dec 29, 2017 | Feb 15, 2018 |
| DEF 14A | Proxy statement | Apr 28, 2017 | Jun 14, 2017 |
| DEF 14A | Proxy statement | Apr 26, 2016 | Jun 16, 2016 |
| DEF 14A | Proxy statement | Aug 17, 2015 | Sep 15, 2015 |
| DEF 14A | Proxy statement | Aug 12, 2014 | Sep 11, 2014 |
| PRE 14A | Preliminary proxy statement | Jul 31, 2014 | Sep 11, 2014 |
| DEF 14A | Proxy statement | Feb 4, 2014 | Mar 13, 2014 |
| PRE 14A | Preliminary proxy statement | Jan 13, 2014 | Mar 13, 2014 |
| DEF 14A | Proxy statement | Nov 4, 2013 | Dec 4, 2013 |
| PRE 14A | Preliminary proxy statement | Oct 24, 2013 | Dec 4, 2013 |
| DEF 14A | Proxy statement | Mar 28, 2013 | Apr 26, 2013 |
| PRE 14A | Preliminary proxy statement | Mar 12, 2013 | Apr 26, 2013 |
| DEF 14A | Proxy statement | Aug 1, 2012 | Aug 31, 2012 |
| PRE 14A | Preliminary proxy statement | Jul 20, 2012 | Aug 31, 2012 |
| DEF 14A | Proxy statement | Sep 6, 2011 | Sep 30, 2011 |
| PRE 14A | Preliminary proxy statement | Aug 19, 2011 | Sep 23, 2011 |
| DEF 14A | Proxy statement | Aug 27, 2010 | Sep 24, 2010 |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TENX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Chapel Hill, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 34956
- Former names
- OXYGEN BIOTHERAPEUTICS, INC. (until Sep 15, 2014); SYNTHETIC BLOOD INTERNATIONAL INC (until Jun 30, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.